ANI Pharmaceuticals (NASDAQ:ANIP) SVP Krista Davis Sells 1,622 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 1,622 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $82.40, for a total transaction of $133,652.80. Following the transaction, the senior vice president directly owned 58,564 shares of the company’s stock, valued at approximately $4,825,673.60. This represents a 2.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $82.85 on Friday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.04 and a current ratio of 2.58. ANI Pharmaceuticals, Inc. has a 1 year low of $52.74 and a 1 year high of $99.50. The firm’s 50-day simple moving average is $86.70 and its 200-day simple moving average is $81.34. The firm has a market cap of $1.86 billion, a PE ratio of 50.83 and a beta of 0.48.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.The firm had revenue of $227.81 million during the quarter, compared to analyst estimates of $211.92 million. During the same period in the previous year, the company earned $1.34 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Equities analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ANIP. Guggenheim lifted their price objective on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday. HC Wainwright boosted their price objective on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Barclays assumed coverage on shares of ANI Pharmaceuticals in a report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 target price on the stock. Finally, JPMorgan Chase & Co. upped their target price on ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $102.14.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Intech Investment Management LLC increased its stake in ANI Pharmaceuticals by 134.7% during the 2nd quarter. Intech Investment Management LLC now owns 26,917 shares of the specialty pharmaceutical company’s stock valued at $1,756,000 after buying an additional 15,447 shares during the period. Envestnet Asset Management Inc. lifted its stake in shares of ANI Pharmaceuticals by 59.9% in the 2nd quarter. Envestnet Asset Management Inc. now owns 10,326 shares of the specialty pharmaceutical company’s stock worth $674,000 after acquiring an additional 3,869 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in shares of ANI Pharmaceuticals in the second quarter valued at approximately $209,000. Sio Capital Management LLC increased its stake in shares of ANI Pharmaceuticals by 29.4% during the second quarter. Sio Capital Management LLC now owns 112,923 shares of the specialty pharmaceutical company’s stock valued at $7,368,000 after acquiring an additional 25,625 shares during the period. Finally, Invesco Ltd. raised its holdings in ANI Pharmaceuticals by 1.0% during the first quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company’s stock worth $13,361,000 after purchasing an additional 2,022 shares in the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.